🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ken Fisher’s PTGX Holdings & Trades

First Buy
Q4 2025
Duration Held
2 Quarters
Largest Add
Q1 2026
+108,857 Shares
Current Position
173,971 Shares
$18.34 M Value

Ken Fisher's PTGX Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 173,971 shares of Protagonist Therapeutics, Inc. (PTGX) worth $18.34 M, representing 0.01% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Ken Fisher has initiated a new position in PTGX, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 108,857 shares.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's Protagonist Therapeutics (PTGX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Protagonist Therapeutics (PTGX) Trades by Ken Fisher

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +108,857 Add 167.18% 173,971 $105.40
Q4 2025 +65,114 New Buy 65,114 $87.34

Ken Fisher's Protagonist Therapeutics Investment FAQs

Ken Fisher first purchased Protagonist Therapeutics, Inc. (PTGX) in Q4 2025, acquiring 65,114 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held Protagonist Therapeutics, Inc. (PTGX) for 2 quarters since Q4 2025.

Ken Fisher's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q1 2026, adding 173,971 shares worth $18.34 M.

According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 173,971 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $18.34 M.

As of the Q1 2026 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.

Ken Fisher's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 173,971 shares, as reported at the end of Q1 2026.